• 2',7'-Dichlorofluorescein Diacetate for ROS

  2026-09-29

  2',7'-Dichlorofluorescein diacetate is a cell-permeable fluorescent ROS probe for intracellular oxidative stress assay workflows. Its signal reports oxidation of intracellular dichlorofluorescein precursor pools, so it is useful for comparative measurements but is not a selective sensor for one reactive species.

• CpAdhE Inhibition by Antifungal Imidazoles

  2026-09-29

  The reference study identifies the bacterial-type bifunctional aldehyde/alcohol dehydrogenase CpAdhE as a chemically vulnerable metabolic target in Cryptosporidium parvum. A tiered screen connected low-micromolar enzyme inhibition by several antifungal imidazoles with suppression of parasite growth in vitro, providing a useful framework for target-based anti-cryptosporidial discovery.

• Frizzled5 Couples Cholesterol to Wnt Signaling

  2026-09-28

  The reference study identifies Frizzled5 as a cholesterol-sensing Wnt receptor that links lipid metabolism to receptor palmitoylation, plasma-membrane trafficking, and β-catenin signaling in pancreatic ductal adenocarcinoma. Its mechanistic framework clarifies why cholesterol supports selected Wnt-dependent tumors and provides a basis for testing receptor-directed metabolic interventions.

• Carbapenemase Transfer in Guangdong CREC Isolates

  2026-09-28

  A study of 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong hospitals combined gene localization, susceptibility testing, conjugation assays, mobile-element analysis, and strain typing. The findings highlight frequent blaNDM-1 carriage, efficient in-vitro transfer of carbapenemase-encoding genes, and evidence of both clonal and horizontal dissemination, while underscoring the limits of a regional observational study.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-09-27

  A phase 3 placebo-controlled trial evaluated daily oral mavorixafor for WHIM syndrome, a rare immunodeficiency caused by dysregulated CXCR4 signaling. The findings summarized in the linked commentary show longer periods with neutrophil and lymphocyte counts above trial-defined thresholds and a lower annualized infection rate, while leaving important questions about long-term outcomes unresolved.

• Doxycycline hyclate for BBB and MMP-2/9 research

  2026-09-26

  Use Doxycycline hyclate to test whether MMP activity connects toxicant exposure with blood–brain barrier damage, neuronal injury, and cognitive change. This workflow translates a 12-week mouse study into practical formulation, assay-selection, and troubleshooting guidance while distinguishing reported findings from suggested pilot conditions.

• Carrier-Platin Triggers Rapid ROS-Driven Cancer Death

  2026-09-25

  Liu et al. report carrier-platin, a platinum nanotherapeutic designed to generate a rapid intracellular reactive oxygen species burst and kill cancer cells through a mechanism distinct from apoptosis, ferroptosis, and DNA damage. The findings support further investigation of ROS catalysis as a strategy against drug-resistant tumors, while leaving important questions about mechanism, delivery, and clinical translation unresolved.

• Tigecycline Workflows for CREC Resistance Research

  2026-09-25

  Use Tigecycline as a mechanistically distinct comparator when studying carbapenem-resistant Enterobacter cloacae (CREC), pairing susceptibility measurements with gene-localization and transfer analyses. This workflow translates hospital surveillance findings into reproducible bench experiments without treating tigecycline response as a proxy for carbapenemase carriage.

• Arsenic, MMP-2/9, and BBB-Linked Cognitive Injury

  2026-09-24

  A 2024 mouse study links chronic sodium arsenite exposure to learning and memory impairment alongside blood–brain barrier (BBB) disruption, increased MMP-2 and MMP-9, and hippocampal neuronal apoptosis. Doxycycline intervention preserved barrier-related features and improved behavioral outcomes, supporting an MMP-associated mechanism while leaving target-specific causality and human relevance unresolved.

• HyperScribe SP6: RNA Design for Immune Assays

  2026-09-24

  The HyperScribe SP6 High Yield RNA Synthesis Kit can support controlled RNA-reagent design for studies of viral immune evasion. This article connects its transcription capabilities to the GADD34–IRF3 findings in SARS-CoV-2 research—and explains key assay controls and limitations.

• GS967 for Cardiac Late Sodium Current Research

  2026-09-23

  Use GS967 to test how excess late sodium influx links prolonged repolarization with calcium loading and impaired relaxation. This guide connects age-stratified cardiac models to practical electrophysiology and arrhythmia workflows, with assay-ready starting conditions and troubleshooting advice.

• Jasplakinolide: Designing Better Actin Assays

  2026-09-23

  Jasplakinolide is an actin polymerization inducer that can expose how filament assembly, stabilization, and cellular response are experimentally linked. This guide combines assay design principles with a critical chemical-genetics perspective to improve interpretation beyond simple cytoskeletal imaging.

• Carbapenemase Transmission in CREC Across Guangdong

  2026-09-22

  A 2025 BMC Microbiology study integrated carbapenemase-gene detection, plasmid localization, conjugation, susceptibility testing, mobile-element analysis, and ERIC-PCR typing across eight Guangdong teaching hospitals. Its central finding was that plasmid-associated blaNDM-1 and efficient horizontal transfer contributed substantially to the dissemination and multidrug-resistant phenotype of carbapenem-resistant Enterobacter cloacae.

• Palomid 529 (P529) in ESCC Pathway Research

  2026-09-22

  Palomid 529 (P529) provides a practical pharmacology tool for testing PI3K/Akt/mTOR signaling in esophageal squamous cell carcinoma, angiogenesis, cisplatin resistance, and radiation-response models. Its dual mTORC1/mTORC2 activity also supports pathway-focused experiments that complement genetic studies of RCN2, PPP2CA, and UBR5.

• Dual-Action p38α Inhibitors Promote Dephosphorylation

  2026-09-21

  The reference preprint shows that selected p38α MAPK inhibitors can do more than occupy the kinase active site: they can also accelerate WIP1-mediated removal of activation-loop phosphate. Structural data link this effect to an inhibitor-stabilized activation-loop conformation that exposes the phospho-threonine, suggesting a strategy for designing kinase inhibitors with both catalytic and phosphatase-assisted activity.

8476 records 1/566 page Next 12345 下5页 Last page